0001193125-22-127921.txt : 20220428 0001193125-22-127921.hdr.sgml : 20220428 20220428170944 ACCESSION NUMBER: 0001193125-22-127921 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220428 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220428 DATE AS OF CHANGE: 20220428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PERRIGO Co plc CENTRAL INDEX KEY: 0001585364 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36353 FILM NUMBER: 22867955 BUSINESS ADDRESS: STREET 1: THE SHARP BUILDING STREET 2: HOGAN PLACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 TY74 BUSINESS PHONE: 269-673-8451 MAIL ADDRESS: STREET 1: 515 EASTERN AVENUE CITY: ALLEGAN STATE: MI ZIP: 49010 FORMER COMPANY: FORMER CONFORMED NAME: PERRIGO Co Ltd DATE OF NAME CHANGE: 20130828 8-K 1 d292050d8k.htm 8-K 8-K
PERRIGO Co plc 00-0000000 false 0001585364 0001585364 2022-04-28 2022-04-28 0001585364 us-gaap:CommonStockMember 2022-04-28 2022-04-28 0001585364 prgo:M4.000NotesDue2023Member 2022-04-28 2022-04-28 0001585364 prgo:M3.900NotesDue2024Member 2022-04-28 2022-04-28 0001585364 prgo:M4.375NotesDue2026Member 2022-04-28 2022-04-28 0001585364 prgo:M3.150NotesDue2030Member 2022-04-28 2022-04-28 0001585364 prgo:M5.300NotesDue2043Member 2022-04-28 2022-04-28 0001585364 prgo:M4.900NotesDue2044Member 2022-04-28 2022-04-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 28, 2022

 

 

Perrigo Company plc

(Exact name of registrant as specified in its charter)

 

 

 

Commission file number 001-36353

 

Ireland   Not Applicable

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74

+353 1 7094000

(Address, including zip code, and telephone number, including

area code, of registrant’s principal executive offices)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Ordinary shares   PRGO   New York Stock Exchange
4.000% Notes due 2023   PRGO23   New York Stock Exchange
3.900% Notes due 2024   PROG24   New York Stock Exchange
4.375% Notes due 2026   PRGO26   New York Stock Exchange
3.150% Notes due 2030   PRGO30   New York Stock Exchange
5.300% Notes due 2043   PRGO43   New York Stock Exchange
4.900% Notes due 2044   PRGO44   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

ITEM 7.01

Regulation FD Disclosure.

On April 28, 2022, Perrigo Company plc issued a press release regarding the expected completion of its previously announced acquisition of Héra SAS on April 29, 2022. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

 

ITEM 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
Number

   

Description

99.1    Press Release issued by Perrigo Company plc on April 28, 2022, furnished solely pursuant to Item 7.01 of Form 8-K
104    Cover Page Interactive Data file (embedded within the Inline XBRL document)

Certain statements in this Current Report on Form 8-K are “forward-looking statements.” These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “forecast,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including: the effect of the coronavirus (COVID-19) pandemic and its variants and the associated supply chain impacts on the Company’s business; general economic, credit, and market conditions; the impact of the war in Ukraine, including the effects of economic and political sanctions imposed by the United States, European Union, and other countries related thereto, and/or the outbreak or escalation of conflict in other regions where we do business; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company’s appeal of the draft and final Notices of Proposed Assessment (“NOPAs”) issued by the U.S. Internal Revenue Service and the impact that an adverse result in any such proceedings would have on operating results, cash flows, and liquidity; pending and potential third-party claims and litigation, including litigation relating to the Company’s restatement of previously-filed financial information and litigation relating to uncertain tax positions, including the NOPAs; potential impacts of ongoing or future government investigations and regulatory initiatives; potential costs and reputational impact of product recalls or sales halts; the impact of tax reform legislation and healthcare policy; the timing, amount and cost of any share repurchases; fluctuations in currency

exchange rates and interest rates; the Company’s ability to achieve the benefits expected from the sale of its Rx business and the risk that potential costs or liabilities incurred or retained in connection with that transaction may exceed the Company’s estimates or adversely affect the Company’s business or operations; the consummation and success of the proposed acquisition of HRA Pharma and the ability to achieve the expected benefits thereof, including the risk that the parties fail to obtain the required regulatory approvals or to fulfill the other conditions to closing on the expected timeframe or at all, the occurrence of any other event, change or circumstance that could delay the transaction or result in the termination of the securities sale agreement or the risks that the Company’s synergy estimates are inaccurate or that the Company faces higher than anticipated integration or other costs in connection with the proposed acquisition; the consummation and success of other announced and unannounced acquisitions or dispositions, and the Company’s ability to realize the desired benefits thereof; and the Company’s ability to execute and achieve the desired benefits of announced cost-reduction efforts and strategic and other initiatives. An adverse result with respect to the Company’s appeal of any material outstanding tax assessments or pending litigation, including securities or drug pricing matters, could ultimately require the use of corporate assets to pay such assessments, damages from third-party claims, and related interest and/or penalties, and any such use of corporate assets would limit the assets available for other corporate purposes. These and other important factors, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2021, as well as the Company’s subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this Current Report on Form 8-K are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    (Registrant)
    PERRIGO COMPANY PLC
    By:  

/s/ Todd W. Kingma

Dated: April 28, 2022

       Todd W. Kingma
      Executive Vice President, General Counsel and Secretary
 EX-99.1 2 d292050dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

FOR IMMEDIATE RELEASE    

PERRIGO ANNOUNCES EXPECTED TRANSACTION CLOSE DATE OF HRA PHARMA

Dublin, Ireland – April 28, 2022 – Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that the closing date of the previously announced acquisition of Héra SAS (“HRA” or “HRA Pharma”) is expected to occur on April 29, 2022, subject to the satisfaction or waiver of the remaining closing conditions set forth in the securities sale agreement.

About Perrigo

Perrigo Company plc (NYSE: PRGO) is a leading provider of Quality, Affordable Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the U.S. in the categories in which it competes through more than 9,000 SKUs under customer ‘own brand’ labels. Additionally, Perrigo is a Top 10 OTC company by revenue in Europe, where it markets more than 200 branded OTC products throughout 28 countries. Visit Perrigo online at www.perrigo.com.

Forward-Looking Statements

Certain statements in this press release are “forward-looking statements.” These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “forecast,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including: the effect of the coronavirus (COVID-19) pandemic and its variants and the associated supply chain impacts on the Company’s business; general economic, credit, and market conditions; the impact of the war in Ukraine, including the effects of economic and political sanctions imposed by the United States, European Union, and other countries related thereto, and/or the outbreak or escalation of conflict in other regions where we do business; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company’s appeal of the draft and final Notices of Proposed Assessment (“NOPAs”) issued by the U.S. Internal Revenue Service and the impact that an adverse result in any such proceedings would have on operating results, cash flows, and liquidity; pending and potential third-party claims and litigation, including litigation relating to the Company’s restatement of previously-filed financial information and litigation relating to

 

1

uncertain tax positions, including the NOPAs; potential impacts of ongoing or future government investigations and regulatory initiatives; potential costs and reputational impact of product recalls or sales halts; the impact of tax reform legislation and healthcare policy; the timing, amount and cost of any share repurchases; fluctuations in currency exchange rates and interest rates; the Company’s ability to achieve the benefits expected from the sale of its Rx business and the risk that potential costs or liabilities incurred or retained in connection with that transaction may exceed the Company’s estimates or adversely affect the Company’s business or operations; the consummation and success of the proposed acquisition of HRA Pharma and the ability to achieve the expected benefits thereof, including the risk that the parties fail to fulfill the conditions to closing on the expected timeframe or at all, the occurrence of any other event, change or circumstance that could delay the transaction or result in the termination of the securities sale agreement or the risks that the Company’s synergy estimates are inaccurate or that the Company faces higher than anticipated integration or other costs in connection with the proposed acquisition; the consummation and success of other announced and unannounced acquisitions or dispositions, and the Company’s ability to realize the desired benefits thereof; and the Company’s ability to execute and achieve the desired benefits of announced cost-reduction efforts and strategic and other initiatives. An adverse result with respect to the Company’s appeal of any material outstanding tax assessments or pending litigation, including securities or drug pricing matters, could ultimately require the use of corporate assets to pay such assessments, damages from third-party claims, and related interest and/or penalties, and any such use of corporate assets would limit the assets available for other corporate purposes. These and other important factors, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2021, as well as the Company’s subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Perrigo Contact

Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications, (269) 686-3373, E-mail: bradley.joseph@perrigo.com

Nicholas Gallagher, Manager, Global Investor Relations & Corporate Communications, (269) 686-3238, E-mail: nicholas.gallagher@perrigo.com

 

2

EX-101.SCH 3 prgo-20220428.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 prgo-20220428_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 prgo-20220428_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Tax Identification Number Entity Tax Identification Number Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] M 4.000 Notes Due 2023 [Member] M 4.000 Notes Due 2023 [Member] M 3.900 Notes Due 2024 [Member] M 3.900 Notes Due 2024 [Member] M 4.375 Notes Due 2026 [Member] M 4.375 Notes Due 2026 [Member] M 3.150 Notes Due 2030 [Member] M 3.150 Notes Due 2030 [Member] M 5.300 Notes Due 2043 [Member] M 5.300 Notes Due 2043 [Member] M 4.900 Notes Due 2044 [Member] M 4.900 Notes Due 2044 [Member] EX-101.PRE 6 prgo-20220428_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g292050g0428235141032.jpg GRAPHIC begin 644 g292050g0428235141032.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 28, 2022
Document And Entity Information [Line Items]  
Entity Registrant Name PERRIGO Co plc
Entity Tax Identification Number 00-0000000
Amendment Flag false
Entity Central Index Key 0001585364
Document Type 8-K
Document Period End Date Apr. 28, 2022
Entity File Number 001-36353
Entity Incorporation State Country Code L2
Entity Address, Address Line One The Sharp Building
Entity Address, Address Line Two Hogan Place
Entity Address, City or Town Dublin 2
Entity Address, Country IE
Entity Address, Postal Zip Code D02 TY74
City Area Code 353 1
Local Phone Number 7094000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Ordinary shares
Trading Symbol PRGO
Security Exchange Name NYSE
M 4.000 Notes Due 2023 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 4.000% Notes due 2023
Trading Symbol PRGO23
Security Exchange Name NYSE
M 3.900 Notes Due 2024 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 3.900% Notes due 2024
Trading Symbol PROG24
Security Exchange Name NYSE
M 4.375 Notes Due 2026 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 4.375% Notes due 2026
Trading Symbol PRGO26
Security Exchange Name NYSE
M 3.150 Notes Due 2030 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 3.150% Notes due 2030
Trading Symbol PRGO30
Security Exchange Name NYSE
M 5.300 Notes Due 2043 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 5.300% Notes due 2043
Trading Symbol PRGO43
Security Exchange Name NYSE
M 4.900 Notes Due 2044 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 4.900% Notes due 2044
Trading Symbol PRGO44
Security Exchange Name NYSE
XML 9 d292050d8k_htm.xml IDEA: XBRL DOCUMENT 0001585364 2022-04-28 2022-04-28 0001585364 us-gaap:CommonStockMember 2022-04-28 2022-04-28 0001585364 prgo:M4.000NotesDue2023Member 2022-04-28 2022-04-28 0001585364 prgo:M3.900NotesDue2024Member 2022-04-28 2022-04-28 0001585364 prgo:M4.375NotesDue2026Member 2022-04-28 2022-04-28 0001585364 prgo:M3.150NotesDue2030Member 2022-04-28 2022-04-28 0001585364 prgo:M5.300NotesDue2043Member 2022-04-28 2022-04-28 0001585364 prgo:M4.900NotesDue2044Member 2022-04-28 2022-04-28 PERRIGO Co plc 00-0000000 false 0001585364 8-K 2022-04-28 001-36353 L2 The Sharp Building Hogan Place Dublin 2 IE D02 TY74 353 1 7094000 false false false false Ordinary shares PRGO NYSE 4.000% Notes due 2023 PRGO23 NYSE 3.900% Notes due 2024 PROG24 NYSE 4.375% Notes due 2026 PRGO26 NYSE 3.150% Notes due 2030 PRGO30 NYSE 5.300% Notes due 2043 PRGO43 NYSE 4.900% Notes due 2044 PRGO44 NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 8 23 1 false 7 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d292050d8k.htm d292050dex991.htm prgo-20220428.xsd prgo-20220428_def.xml prgo-20220428_lab.xml prgo-20220428_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d292050d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 8, "dts": { "definitionLink": { "local": [ "prgo-20220428_def.xml" ] }, "inline": { "local": [ "d292050d8k.htm" ] }, "labelLink": { "local": [ "prgo-20220428_lab.xml" ] }, "presentationLink": { "local": [ "prgo-20220428_pre.xml" ] }, "schema": { "local": [ "prgo-20220428.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 35, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 6, "memberStandard": 1, "nsprefix": "prgo", "nsuri": "http://www.perrigo.com/20220428", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d292050d8k.htm", "contextRef": "duration_2022-04-28_to_2022-04-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d292050d8k.htm", "contextRef": "duration_2022-04-28_to_2022-04-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 7, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "prgo_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.perrigo.com/20220428", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "prgo_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.perrigo.com/20220428", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "prgo_M3.150NotesDue2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "M 3.150 Notes Due 2030 [Member]", "terseLabel": "M 3.150 Notes Due 2030 [Member]" } } }, "localname": "M3.150NotesDue2030Member", "nsuri": "http://www.perrigo.com/20220428", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "prgo_M3.900NotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "M 3.900 Notes Due 2024 [Member]", "terseLabel": "M 3.900 Notes Due 2024 [Member]" } } }, "localname": "M3.900NotesDue2024Member", "nsuri": "http://www.perrigo.com/20220428", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "prgo_M4.000NotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "M 4.000 Notes Due 2023 [Member]", "terseLabel": "M 4.000 Notes Due 2023 [Member]" } } }, "localname": "M4.000NotesDue2023Member", "nsuri": "http://www.perrigo.com/20220428", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "prgo_M4.375NotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "M 4.375 Notes Due 2026 [Member]", "terseLabel": "M 4.375 Notes Due 2026 [Member]" } } }, "localname": "M4.375NotesDue2026Member", "nsuri": "http://www.perrigo.com/20220428", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "prgo_M4.900NotesDue2044Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "M 4.900 Notes Due 2044 [Member]", "terseLabel": "M 4.900 Notes Due 2044 [Member]" } } }, "localname": "M4.900NotesDue2044Member", "nsuri": "http://www.perrigo.com/20220428", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "prgo_M5.300NotesDue2043Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "M 5.300 Notes Due 2043 [Member]", "terseLabel": "M 5.300 Notes Due 2043 [Member]" } } }, "localname": "M5.300NotesDue2043Member", "nsuri": "http://www.perrigo.com/20220428", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.perrigo.com//20220428/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001193125-22-127921-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-127921-xbrl.zip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